The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
The Notch ligand Jagged1 as a target for anti-tumor therapy
Open accessAbstract
The Notch pathway is increasingly attracting attention as a source of therapeutic targets for cancer. Ligand-induced Notch signaling has been implicated in various aspects of cancer biology; as a consequence, pan-Notch inhibitors and therapeutic antibodies targeting one or more of the Notch receptors have been investigated for cancer therapy. Alternatively, Notch ligands provide attractive options for therapy in cancer treatment due to their more restricted expression and better-defined functions, as well as their low rate of mutations in cancer. One of the Notch ligands, Jagged1 (JAG1), is overexpressed in many cancer types, and plays an important role in several aspects of tumor biology. In fact, JAG1-stimulated Notch activation is directly implicated in tumor growth through maintaining cancer stem cell populations, promoting cell survival, inhibiting apoptosis, and driving cell proliferation and metastasis. In addition, JAG1 can indirectly affect cancer by influencing tumor microenvironment components such as tumor vasculature and immune cell infiltration. This article gives an overview of JAG1 and its role in tumor biology, and its potential as a therapeutic target.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular mechanisms of epithelial–mesenchymal transition
Lamouille, S., Xu, J., & Derynck, R. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3758 · Cited by 8,091
Modes of resistance to anti-angiogenic therapy
Bergers, G., & Hanahan, D. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2442 · Cited by 2,953 · cited 1×
“Increased pericyte coverage of the tumor vasculature that maintains its integrity is thought to be one of the main mechanisms that cause resistance to anti-angiogenic treatments (156).”
BackgroundThe tumor microenvironment and its role in promoting tumor growth
Whiteside, T. L. (2008) · Oncogene · doi:10.1038/onc.2008.271 · Cited by 2,376
Tschaharganeh, D. F., Chen, X., Latzko, P., Malz, M., Gaida, M. M., Felix, K., Ladu, S., Singer, S., Pinna, F., Gretz, N., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.02.009 · Cited by 326
Chronic DLL4 blockade induces vascular neoplasms
Yan, M., Callahan, C. A., Beyer, J. C., Allamneni, K. P., Zhang, G., Ridgway, J. B., Niessen, K., & Plowman, G. D. (2010) · Nature · doi:10.1038/nature08751 · Cited by 280
Notch activation inhibits AML growth and survival: a potential therapeutic approach
Kannan, S., Sutphin, R. M., Hall, M. G., Golfman, L. S., Fang, W., Nolo, R. M., Akers, L. J., Hammitt, R. A., McMurray, J. S., Kornblau, S. M., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20121527 · Cited by 152
Cited by
Implications of the Hybrid Epithelial/Mesenchymal Phenotype in Metastasis
Jolly, M. K. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00155 · Cited by 693
Signaling pathways involved in colorectal cancer progression
Koveitypour, Z., Panahi, F., Vakilian, M., Peymani, M., Seyed Forootan, F., Nasr Esfahani, M. H., & Ghaedi, K. (2019) · Cell & Bioscience · doi:10.1186/s13578-019-0361-4 · Cited by 393
EMT and MET : necessary or permissive for metastasis?
Jolly, M. K., Ware, K. E., Gilja, S., Somarelli, J. A., & Levine, H. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12083 · Cited by 371
Notch Signaling and the Skeleton
Zanotti, S., & Canalis, E. (2016) · Endocrine Reviews · doi:10.1210/er.2016-1002 · Cited by 321
Toward understanding cancer stem cell heterogeneity in the tumor microenvironment
Bocci, F., Gearhart-Serna, L., Boareto, M., Ribeiro, M., Ben-Jacob, E., Devi, G. R., Levine, H., Onuchic, J. N., & Jolly, M. K. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1815345116 · Cited by 299
Metadata
- Authors
- Li, D.
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2014
- Volume
- 4
- Pages
- 254-254
- ISSN
- 2234-943X (ISSN-L)
- OpenAlex
- W2075663237
- Cited by
- 187
- References
- 6
- FWCI
- 6.69
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Notch ligand Jagged1 as a target for anti-tumor therapy. https://app.cochat.ai/papers/10.3389/fonc.2014.00254
- The paper
- Li, D. (2014). The Notch ligand Jagged1 as a target for anti-tumor therapy. Frontiers in Oncology. https://doi.org/10.3389/fonc.2014.00254
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.